Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.

Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
复制标题

DOI:
10.1054/bjoc.2000.1690
复制
发表时间:
2001-04-06
影响因子:
8.8
通讯作者:
Itoh K
Itoh K
中科院分区:
医学1区
文献类型:
--
作者:
Suefuji Y;Sasatomi T;Shichijo S;Nakagawa S;Deguchi H;Koga T;Kameyama T;Itoh K

文献摘要

参考文献

被引文献

相似文献

我们最近报道了SART 3肿瘤排斥抗原具有能够诱导HLA-I类限制性细胞毒性T淋巴细胞(CTL)的肿瘤表位。本研究调查SART 3抗原在乳腺癌中的表达,以探索用于乳腺癌患者特异性免疫治疗的合适分子。SART 3抗原在所有测试的乳腺癌细胞系、40个乳腺癌组织样品中的30个(75%)和3个非肿瘤乳腺组织样品中的0个中检测到。在位置109-118和315-323处的SART 3衍生肽诱导HLA-A24限制性CTL,所述CTL与来自乳腺癌患者的外周血单核细胞(PBMC)的乳腺癌细胞反应。因此,SART 3抗原及其肽可能是用于大多数HLA-A24阳性乳腺癌患者的特异性免疫治疗的合适分子。© 2001年癌症研究运动http:www.bjcancer.com
We recently reported the SART3 tumour-rejection antigen as possessing tumour epitopes capable of inducing HLA-class I-restricted cytotoxic T lymphocytes (CTLs). This study investigated expression of the SART3 antigen in breast cancer to explore an appropriate molecule for use in specific immunotherapy of breast cancer patients. The SART3 antigen was detected in all of the breast cancer cell lines tested, 30 of 40 (75%) breast cancer tissue samples, and 0 of 3 non-tumourous breast tissue samples. SART3 derived peptides at positions 109–118 and 315–323 induced HLA-A24 restricted CTLs that reacted to breast cancer cells from the peripheral blood mononuclear cells (PBMCs) of breast cancer patients. Therefore, the SART3 antigen and its peptides could be an appropriate molecule for use in specific immunotherapy of the majority of HLA-A24-positive breast cancer patients. © 2001 Cancer Research Campaignhttp://www.bjcancer.com
DOI: 10.1084/jem.179.3.921
发表时间: 1994-03-01
期刊: The Journal of experimental medicine
影响因子: --
作者:
Gaugler B;Van den Eynde B;van der Bruggen P;Romero P;Gaforio JJ;De Plaen E;Lethé B;Brasseur F;Boon T
通讯作者: Boon T
DOI: 10.1038/nm0398-321
发表时间: 1998-03-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Rosenberg, SA;Yang, JC;White, DE
通讯作者: White, DE
DOI: 10.1038/nm0398-328
发表时间: 1998-03-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Nestle, FO;Alijagic, S;Schadendorf, D
通讯作者: Schadendorf, D
DOI: 10.1038/sj.gt.3300489
发表时间: 1997-10-01
期刊: GENE THERAPY
影响因子: 5.1
作者:
Traversari, C;Meazza, R;Ferrini, S
通讯作者: Ferrini, S
DOI: 10.1084/jem.180.1.347
发表时间: 1994-07-01
期刊: The Journal of experimental medicine
影响因子: --
作者:
Kawakami Y;Eliyahu S;Sakaguchi K;Robbins PF;Rivoltini L;Yannelli JR;Appella E;Rosenberg SA
通讯作者: Rosenberg SA